Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group

Tamara N. Shenkier, Jean Yves Blay, Brian Patrick O'Neill, Philip Poortmans, Eckhard Thiel, Kristoph Jahnke, Lauren E. Abrey, Edward Neuwelt, Richard Tsang, Tracy Batchelor, Nancy Harris, Andrés J.M. Ferreri, Maurilio Ponzoni, Peter O'Brien, James Rubenstein, Joseph M. Connors

Research output: Contribution to journalArticle

126 Scopus citations

Abstract

Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.

Original languageEnglish (US)
Pages (from-to)2233-2239
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number10
DOIs
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group'. Together they form a unique fingerprint.

  • Cite this

    Shenkier, T. N., Blay, J. Y., O'Neill, B. P., Poortmans, P., Thiel, E., Jahnke, K., Abrey, L. E., Neuwelt, E., Tsang, R., Batchelor, T., Harris, N., Ferreri, A. J. M., Ponzoni, M., O'Brien, P., Rubenstein, J., & Connors, J. M. (2005). Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS Lymphoma Collaborative Group. Journal of Clinical Oncology, 23(10), 2233-2239. https://doi.org/10.1200/JCO.2005.07.109